Related Experiment Video

Updated: May 7, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K

Neuroendocrine differentiation in acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor

Youjin Chang1, Seon Ye Kim, Yun Jung Choi

  • 1Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Tuberculosis and Respiratory Diseases
|October 9, 2013
PubMed
Abstract

Insights

Small cell lung cancer (SCLC) can develop neuroendocrine (NE) differentiation as a resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). This NE differentiation in lung cancer cells increases sensitivity to standard SCLC chemotherapy drugs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Small cell lung cancer (SCLC) transformation is a proposed mechanism of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung cancer.
  • Understanding resistance mechanisms is crucial for improving lung cancer treatment strategies.

Purpose of the Study:

  • To investigate SCLC transformation and neuroendocrine (NE) differentiation in EGFR-TKI-resistant lung cancer cell lines.
  • To determine the impact of NE differentiation on the efficacy of conventional SCLC chemotherapeutic drugs.

Main Methods:

  • Established EGFR-TKI-resistant lung adenocarcinoma cell lines (A549, PC-9, HCC827).
  • Analyzed resistant cell lines for markers of NE differentiation (CD56, synaptophysin, Rb, p16) using western blotting.
  • Assessed sensitivity of NE-differentiated cells to etoposide and cisplatin.
  • Induced NE differentiation in A549 cells using cAMP and IBMX.
  • Examined a patient tissue sample for NE markers after erlotinib resistance developed.

Main Results:

  • Two resistant cell lines, A549/GR and PC-9/ZDR, exhibited increased CD56 expression.
  • A549/GR cells showed additional NE markers (synaptophysin, Rb, p16), indicating NE differentiation.
  • A549/GR cells demonstrated increased sensitivity to etoposide and cisplatin compared to parental cells.
  • Induced NE differentiation in A549 cells also enhanced sensitivity to etoposide and cisplatin.
  • A patient's tumor sample revealed increased CD56 and synaptophysin after developing erlotinib resistance.

Conclusions:

  • Neuroendocrine (NE) differentiation is a viable mechanism of resistance to EGFR-TKIs in lung cancer.
  • Acquisition of NE differentiation can lead to increased sensitivity to standard SCLC chemotherapeutic agents.
  • Findings support the potential for targeting NE differentiation in resistant lung cancer cases.
Keywords:
Cell Transformation, NeoplasticDrug Resistance, NeoplasmSmall Cell Lung Carcinoma

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

9.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
64.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84